Clinical Trial Details

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Categories (click each to see list of all clinical trials associated with that category): Lymphoma/CLL (ONC)

Current Status: Open

Phase: I (Cancer Control)

Principal Investigator: D'Angelo, Christopher

Contact Information:
Maribeth Hohenstein, RN
402-559-9053
mahohens@unmc.edu

Eligibility: https://clinicaltrials.gov/study/NCT03328078?term=NCT03328078&rank=1

Summary
Parts A1 and A2 (Dose Escalation Phase): To determine the safety and tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral emavusertib as monotherapy and in combination with ibrutinib Part B: To assess the anti-cancer activity of emavusertib in combination with ibrutinib in patients with R/R PCNSL Part C: To assess the anti-cancer activity of emavusertib as monotherapy, ibrutinib as monotherapy, and emavusertib in combination with ibrutinib in patients with R/R PCNSL.